Literature DB >> 14699048

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Benjamin S Braun1, David A Tuveson, Namie Kong, Doan T Le, Scott C Kogan, Jacob Rozmus, Michelle M Le Beau, Tyler E Jacks, Kevin M Shannon.   

Abstract

RAS mutations are common in myeloid malignancies; however, it is not known whether oncogenic RAS can initiate leukemia. We show that expressing mutant K-Ras(G12D) protein from the endogenous murine locus rapidly induces a fatal myeloproliferative disorder with 100% penetrance characterized by tissue infiltration, hypersensitivity to growth factors, and hyperproliferation. Hematopoietic cells from diseased mice demonstrated increased levels of Ras-GTP, but effector kinases were not constitutively phosphorylated and responded normally to growth factors. Oncogenic RAS is sufficient to initiate myeloid leukemogenesis in mice, and this provides an in vivo system for biologic and preclinical studies.

Entities:  

Mesh:

Year:  2003        PMID: 14699048      PMCID: PMC327193          DOI: 10.1073/pnas.0307203101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

Review 2.  Signaling networks: the origins of cellular multitasking.

Authors:  J D Jordan; E M Landau; R Iyengar
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 3.  The GTPase superfamily: conserved structure and molecular mechanism.

Authors:  H R Bourne; D A Sanders; F McCormick
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

Authors:  T Okuda; Z Cai; S Yang; N Lenny; C J Lyu; J M van Deursen; H Harada; J R Downing
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

6.  Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders.

Authors:  L Side; B Taylor; M Cayouette; E Conner; P Thompson; M Luce; K Shannon
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

7.  Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15).

Authors:  K Yamamoto; Y Nakamura; K Saito; S Furusawa
Journal:  Br J Haematol       Date:  2000-05       Impact factor: 6.998

8.  Introduction of an activated RAS oncogene into murine bone marrow lymphoid progenitors via retroviral gene transfer results in thymic lymphomas.

Authors:  C E Dunbar; P S Crosier; A W Nienhuis
Journal:  Oncogene Res       Date:  1991

9.  Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.

Authors:  K L MacKenzie; A Dolnikov; M Millington; Y Shounan; G Symonds
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

10.  Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis.

Authors:  A Bashey; R Gill; S Levi; C J Farr; R Clutterbuck; J L Millar; I B Pragnell; C J Marshall
Journal:  Blood       Date:  1992-02-15       Impact factor: 22.113

View more
  142 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Authors:  Jin Xu; Christian Hedberg; Frank J Dekker; Qing Li; Kevin M Haigis; Eugene Hwang; Herbert Waldmann; Kevin Shannon
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

3.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

4.  An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.

Authors:  Jaroslaw Daniluk; Yan Liu; Defeng Deng; Jun Chu; Haojie Huang; Sebastian Gaiser; Zobeida Cruz-Monserrate; Huamin Wang; Baoan Ji; Craig D Logsdon
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

5.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

Authors:  Julie E Niemela; Lianghao Lu; Thomas A Fleisher; Joie Davis; Iusta Caminha; Marc Natter; Laurel A Beer; Kennichi C Dowdell; Stefania Pittaluga; Mark Raffeld; V Koneti Rao; João B Oliveira
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

6.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

8.  GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.

Authors:  Anna-Karin M Sjogren; Karin M E Andersson; Meng Liu; Briony A Cutts; Christin Karlsson; Annika M Wahlstrom; Martin Dalin; Carolyn Weinbaum; Patrick J Casey; Andrej Tarkowski; Birgitta Swolin; Stephen G Young; Martin O Bergo
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

10.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.